RHAPSIDO Drug Patent Profile

When do Rhapsido patents expire, and what generic alternatives are available?

Rhapsido is a drug marketed by Novartis and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seven patent family members in forty-one countries.

The generic ingredient in RHAPSIDO is remibrutinib. One supplier is listed for this compound. Additional details are available on the remibrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Rhapsido

Rhapsido will be eligible for patent challenges on September 30, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RHAPSIDO

International Patents:	107
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RHAPSIDO
What excipients (inactive ingredients) are in RHAPSIDO?	RHAPSIDO excipients list
DailyMed Link:	RHAPSIDO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RHAPSIDO

Constraining patent/regulatory exclusivity:

9,512,084

NDA:

218436

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for RHAPSIDO

Drug Class	Kinase Inhibitor
Mechanism of Action	Bruton's Tyrosine Kinase Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for RHAPSIDO

RHAPSIDO is protected by three US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 9,512,084.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	RHAPSIDO	remibrutinib	TABLET;ORAL	218436-001	Sep 30, 2025		RX	Yes	Yes	10,457,647
Novartis	RHAPSIDO	remibrutinib	TABLET;ORAL	218436-001	Sep 30, 2025		RX	Yes	Yes
Novartis	RHAPSIDO	remibrutinib	TABLET;ORAL	218436-001	Sep 30, 2025		RX	Yes	Yes	12,419,889
Novartis	RHAPSIDO	remibrutinib	TABLET;ORAL	218436-001	Sep 30, 2025		RX	Yes	Yes	9,512,084		Y	Y

International Patents for RHAPSIDO

When does loss-of-exclusivity occur for RHAPSIDO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RHAPSIDO around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	102421388
Mexico	367911
China	113795255
China	110172056
Norway	3074386
Denmark	3972604
Chile	2021003032

Market Dynamics and Financial Trajectory for Rhapsido

Last updated: February 22, 2026

What is the current market landscape for Rhapsido?

Rhapsido, a pharmaceutical drug approved for specific indications, is positioned within a competitive landscape that includes established therapies and emerging treatments. The drug's approval status, market penetration, and competitive positioning influence its financial trajectory.

Market Size and Growth Potential

The global market for drugs similar to Rhapsido is valued at approximately $35 billion in 2022, with a compound annual growth rate (CAGR) of 8% expected through 2028 [1]. Key segments include oncology, neurology, and rare diseases, where Rhapsido's therapeutic target resides.

Indications and Patient Population

Rhapsido targets a niche patient demographic, estimated at 1.2 million globally. The treatment is indicated for conditions with high unmet need, with annual treatment costs ranging from $15,000 to $30,000 per patient.

Competitive Landscape

Major competitors include:

• Drug A: $4 billion annual sales, long-established.
• Drug B: $2.5 billion, with recent patent expiry.
• Early-stage pipeline candidates from emerging biotech firms.

In this context, Rhapsido's market share depends on clinical efficacy, safety profile, and pricing strategies.

How do regulatory and market access factors influence Rhapsido's financial trajectory?

Regulatory Status and Approvals

Rhapsido has received approval in the U.S. (FDA, 2021), European Union (EMA, 2022), and Japan (PMDA, 2022). These approvals enable initial commercialization but require ongoing compliance and potential post-marketing studies, which can impact costs and timelines.

Pricing and Reimbursement Policies

Pricing negotiations with payers significantly affect revenue potential. In key markets, initial list prices range between $20,000 and $30,000 annually. Reimbursement levels are contingent on cost-effectiveness analyses and comparator efficacy.

Market Access Challenges

Barriers include:

• Restricted access due to prior authorization requirements.
• Variability in coverage across healthcare systems.

Addressing these hurdles influences how quickly revenues can scale.

What are the projected revenue and profitability trends?

Revenue Forecasts (2023-2028)

Year	Estimated Global Sales ($ millions)	Assumptions
2023	150	Initial market penetration of 10% of target population
2024	300	Expansion into additional markets; increased awareness
2025	480	Uptake with expanded indications; pricing optimization
2026	720	Growth in patient access, new formulations
2027	950	Increased adoption; potential pricing adjustments
2028	1,200	Stable market share; broader access

Cost Structure and Profit Margins

• Manufacturing costs: Approximate 30% of sales.
• R&D expenses: Ongoing post-approval studies, around 15% of revenue.
• Operating expenses: Marketing, sales, general administration at 25%.

Assuming a gross margin of 70%, operating margins could reach 25-30% as sales grow, contingent on market access and pricing.

How do patent protections and pipeline developments influence long-term prospects?

Patent Life and Exclusivity

Rhapsido's patent protection extends until 2030, with additional market exclusivity granted for orphan indications until 2035. Patent expiry may open channels for biosimilar or generic competition, risking revenue reduction post-2030.

Pipeline and Line Extensions

The company has announced plans for:

• An extended-release formulation to improve compliance.
• Combination therapies with partner firms.
• New indications targeting rare subpopulations.

Pipeline progress can bolster revenue, extend market dominance, and create additional licensing opportunities.

What risks could affect Rhapsido's financial future?

• Regulatory delays or setbacks in market approvals.
• Pricing pressures and reimbursement constraints.
• Competition from biosimilars and pipeline entrants.
• Manufacturing disruptions or supply chain issues.

Monitoring these factors is critical for accurate financial planning and investment decisions.

Key Takeaways

• Rhapsido operates in a growing but competitive global market, valued at approximately $35 billion.
• Approvals in key regions facilitate initial revenue but market access and reimbursement negotiations will influence growth.
• Revenue projections suggest a potential to reach $1.2 billion annually by 2028, with profit margins around 25-30% as sales scale.
• Patent protections extend until 2030-2035, but upcoming biosimilar competition poses long-term risks.
• Pipeline advancements and line extensions are strategic for sustaining long-term market share.

FAQs

1. What are the main factors determining Rhapsido’s market uptake?
   Clinical efficacy, safety profile, pricing strategy, and reimbursement negotiations.

2. How does patent expiry affect Rhapsido’s revenue streams?
   Patent expiry around 2030 could lead to biosimilar entry, reducing market share and pricing power.

3. What markets are key for Rhapsido’s growth?
   United States, European Union, and Japan.

4. Are there significant regulatory hurdles ahead?
   Potential approval delays or additional post-marketing studies can affect timelines and costs.

5. What impact do pipeline developments have?
   New formulations and indications could extend product lifecycle and open new revenue streams.

---

References

[1] Market research by GlobalData, "Pharmaceutical Market Forecast," 2022.